John Freeman, MD
Ophthalmology · Memphis, TNNPI 1538168455
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $127,500 of the $135,720 with a category attached, or 93.9%. Grace Medical, Inc. accounts for 93.9% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $128,007 and has fallen 99.9% since, to $111 in 2025. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $936.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grace Medical, Inc.$128K
- Rxsight Inc$6K
- Johnson & Johnson Surgical Vision, Inc.$460
- AbbVie$448
- Alcon$338
- Bausch & Lomb Americas Inc.$185
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,7832%
- Education$5,4374%
- Ownership interest$127,50094%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grace Medical, Inc. | 1 | $127,500 |
| Rxsight Inc | 11 | $5,518 |
| Johnson & Johnson Surgical Vision, Inc. | 20 | $460 |
| AbbVie(2 entities) | 20 | $448 |
| Alcon | 12 | $338 |
| Bausch & Lomb Americas Inc. | 10 | $185 |
| Mallinckrodt Hospital Products Inc. | 5 | $162 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $149 |
| Novartis | 9 | $143 |
| Shire North American Group Inc | 9 | $117 |
| Biotissue Holdings Inc. | 5 | $86 |
| Oyster Point Pharma, Inc. | 4 | $78 |
| Kala Pharmaceuticals, Inc. | 5 | $64 |
| Aerie Pharmaceuticals, Inc. | 4 | $59 |
| Amgen | 3 | $55 |
| Harrow Eye, LLC | 3 | $55 |
| NEW World Medical,inc. | 1 | $50 |
| Carl Zeiss Meditec USA, Inc. | 2 | $47 |
| Ocular Therapeutix, Inc. | 2 | $36 |
| Dompe US, Inc. | 2 | $36 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Vertex | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Thea Pharma Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$135,720 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 242 | $311,631 |
| XiidraLifitegrast | 35 | $41,313 |
| Cyclosporine | 52 | $29,593 |
| RocklatanNetarsudil Mesylat/Latanoprost | 38 | $21,243 |
| LumiganBimatoprost | 35 | $18,814 |
| CombiganBrimonidine Tartrate/Timolol | 44 | $16,702 |
| Loteprednol Etabonate | 83 | $14,455 |
| Brimonidine Tartrate | 158 | $11,865 |
| RhopressaNetarsudil Mesylate | 15 | $11,416 |
| ProlensaBromfenac Sodium | 32 | $10,986 |
| Timolol Maleate | 177 | $10,082 |
| Prednisolone Acetate | 189 | $8,223 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 34 | $8,175 |
| Bromfenac Sodium | 22 | $6,287 |
| Lotemax SmLoteprednol Etabonate | 22 | $5,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $448 | $351,051332 claims |
| Bausch & Lomb Americas Inc.Xiidra | $185 | $41,31335 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $59 | $32,65953 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm | $149 | $31,186137 claims |
| NovartisIlevro | $143 | $5,57114 claims |
| AlconSimbrinza | $338 | $2,22711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Memphis
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian FowlerMemphis$206K
- Brian JerkinsMemphis$150K
- James FreemanMemphis$141K
- Penny AsbellMemphis$131K
- Kourtney HouserMemphis$104K
- Subba GollamudiMemphis$67K
- Andrew CrothersMemphis$13K
- Brian SmithMemphis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.